Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843448 | 0.87 | L3MBTL1 (0.46) | BCHECA12CA1L3MBTL1MEN1 | |
| SCHEMBL2845744 | 0.85 | BRD4 (0.45) | BCHECA1L3MBTL1MEN1KMT2A | |
| SCHEMBL2838329 | 0.83 | BCHE (0.48) | BCHEL3MBTL1MEN1KMT2ABRD4 | |
| SCHEMBL2846431 | 0.80 | STK17B (0.45) | BCHEL3MBTL1MEN1KMT2ABRD4 | |
| SCHEMBL752391 | 0.80 | CA1 (0.54) | IDO1CA12CA1CA7CA14 | |
| SCHEMBL2842705 | 0.78 | STK17B (0.47) | BCHEMEN1KMT2ABRD4GAA | |
| SCHEMBL22605044 | 0.78 | ATM (0.58) | BCHEIDO1CA12CA1CA7 | |
| SCHEMBL894822 | 0.78 | ATM (0.58) | BCHEIDO1CA12CA1CA7 | |
| SCHEMBL16748723 | 0.76 | STK17B (0.41) | BCHEMEN1KMT2ABRD4MALT1 | |
| SCHEMBL3838871 | 0.76 | CA12 (0.63) | IDO1CA12CA1CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145879-B1 | Pyrazine derivatives, methods of use, and methods for preparing same | MEDIBEACON LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2145879-B1 | Pyrazine derivatives, methods of use, and methods for preparing same | MEDIBEACON LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8481734-B2 | Pyrazine derivatives and uses thereof, including in medical imaging and visualization applications | MEDIBEACON DEVELOPMENT LLC (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100021382-A1 | Pyrazine Derivatives and Uses Thereof | MALLINCKRODT INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-2145879-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2145879-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | MALLINCKRODT INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | MALLINCKRODT INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2143716-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2143716-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | DPYD, DHPS, DHX15 | BCHE 2216/4885IDO1 1220/4885CA12 2020/4885 |
| US-20100021382-A1 | Pyrazine Derivatives and Uses Thereof | DPYD, PRDX5, NOX5 | BCHE 2945/4885IDO1 2260/4885CA12 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.